The synthesis of 3-substituted L-fuco-azafagomines from D-lyxose is reported. They represent the first example of aza-C-glycosides having a biimino (-NH-NH-) moiety. The key step of the synthesis is the introduction of the hydrazine moiety by reductive hydrazination of a 1-deoxy-ketohexose with tert-butyl carbazate. Their glycosidase inhibitory properties are also reported.
a-L-Fucosidase is an exoglycosidase involved in the trimming of nonreducing terminal L-fucose units during the biosynthetic processing of fucose-containing glycoconjugates. 1 This enzyme, in common with other glycosidases, has glycosyl transfer activity and, therefore, can be also used in the synthesis of fucosyl glycans.
2 a-L-Fucosidase is associated with a great variety of physiological and pathological events. For example, aberrant distribution of fucose on fucose-containing glycoconjugates is found in inflammation processes, cancer, and cystic fibrosis. 3 Inhibitors of a-L-fucosidase can provide useful information about the functions of the enzyme and the basis for the development of potential therapeutic agents. 4 Among the most powerful a-L-fucosidase inhibitors are Lfuco hydroxylated piperidines such as L-fuconojirimycin (FNJ, 1), 5 although the intrinsic instability caused by the lability of the N,O-acetal function prevents its biological use. The 1-hydroxymethyl-FNJ 6 and 1-aminomethyl-FNJ, 7 which have a C-C bond at C-1, are stable C-glycosyl analogues 8 that have been used to generate potent inhibitors of a-L-fucosidases.
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On the other hand, Bols and co-workers have described the preparation of (3S,4R,5S)-3-methylhexahydropyridazine-4,5-diol (2), the so-called 'fuco-azafagomine' (Figure 1 ) that showed interesting inhibitory properties. 10 To the best of our knowledge, 2 is the only reported example of a L-fuco polyhydroxylated hexahydropyridazine.
We report herein for the first time the synthesis and the glycosidase inhibitory properties of the C-3 substituted fuco-azafagomines 3a and 3b. Both compounds can be used as new leads in the search for selective and potent inhibitors of a-L-fucosidases. The hydroxylated L-fucohexahydropyridazine moiety can be used as core structure to mimic the fucosyl cation generated in the enzymatic hydrolysis. Besides, the hydroxymethyl or aminomethyl groups at C-3 can be further functionalized giving a library of derivatives by a diversity-oriented synthesis. These compounds could contribute to a better understanding of the inhibition mechanisms of fucosidases in terms of structural and conformational changes, charge dislocation, and protonation as it has been made with azafagomine analogues in glucosidases.
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The retrosynthetic analysis for the preparation of compounds 3a and 3b is indicated in Scheme 1. The key steps imply cyclization of 2-methyl glycosylhydrazines, which were obtained by reductive hydrazination of a 1-deoxyketohexose easily prepared from D-lyxose, which contains the correct configuration at C-4 and C-5 of our target compounds.
Scheme 1
Thus, starting from D-lyxose, tri-O-protected D-lyxonolactone 5 could be easily obtained following a similar procedure to that described in the literature 12 (Scheme 2). Addition of MeLi 13 afforded the protected 1-deoxy-ketohexose 6 as a 3:1 mixture of anomers. Reductive hydrazination of 6 using tert-butyl carbazate, NaBH 3 CN, and acetic acid in MeOH at 65 °C afforded the mixture of hydrazines 7 in 82% yield. Reaction of 7 with benzyl chloroformate, followed by mesylation and selective Boc deprotection gave crude monohydrazides that were treat- 
ed with Et 3 N in MeOH at reflux to afford cyclic derivatives 8 and 9 as a 2.1:1 mixture of diastereomers. This sequence could be efficiently carried out without intermediate purification, affording the corresponding hexahydropyridazines in 71% overall yield after chromatographic separation.
Scheme 2
Compounds 8 and 9 were fully characterized by their spectroscopic data 14 but the configuration of C-6 was difficult to assign. Fortunately, deprotection of 8 followed by tosylation afforded crystalline tosyl derivative 10, the structure of which was unambiguously confirmed by Xray crystallography (Figure 2) . 15 The 1 H NMR spectrum of 9 showed a large coupling constant (J = 9.3 Hz) between H-3 and H-4 and no coupling constant between H-5 and H-6. These results together with a coupling constant of 5.0 Hz between H-4 and H-5 indicated that 9 had a chair conformation with the C-3 substituent in equatorial and the Me-6 in axial positions. However, although the X-ray structure of 10 indicated a chair conformation, its 1 H NMR spectrum 16 showed coupling constant values of 4.5, 5.5 and 5.5 Hz for J 3,4 , J 4,5 , and J 5,6 , respectively. These values were also observed for compound 8, which indicates that a conformational equilibrium for both derivatives takes place in solution.
Reaction of 10 with TBAN 3 followed by reduction of the azido group with H 2 S afforded protected aminomethyl derivative 11.
Figure 2 X-ray crystallographic structure for compound 10
Hydrogenation of compound 8 afforded hydrazone 12 in good yield. The formation of this product can be explained by oxidation of the hydrazine to the corresponding azo compound, followed by isomerization of the double bond to the more stable hydrazone. 17 Then, deprotection of compounds 8 and 9 was attempted by treatment with TBAF, followed by acidic removal of the acetonide affording N-protected alcohols 13 and 14 in good to excellent yields. Final hydrogenation of these compounds under acidic conditions afforded desired hydroxylated hexahydropyridazines 3a and 15, 18 in quantitative yields as the corresponding hydrochloride salts. Acidic treatment of 11 and subsequent catalytic hydrogenation furnished compound 3b as hydrochloride salt in excellent overall yield (Scheme 3). Hydrogenation under acidic conditions is critical to avoid undesired oxidation.
Derivatives 3a, 3b, and 15 have been analyzed for their inhibitory activities towards twelve commercially available glycosidases (Table 1) . 19 Compound 3a was a selective and competitive inhibitor of a-L-fucosidase from bovine kidney (97% at 1 mM concentration,
is a comparable value to that reported for fuco-azafagomine 2, 10 showing that the C-3 substituent is not detrimental for the inhibition. It is worth noting that compound 3a did not inhibit any of the other enzymes assayed: a-galactosidases from coffee beans, b-galactosidases from Escherichia coli and Aspergillus orizae, a-glucosidases from yeast and from rice, amyloglucosidase from Aspergillus niger, b-glucosidases from almonds, a-mannosidases from Jack beans, b-mannosidases from snail, b-xylosidases from Aspergillus niger, and b-N-acetylglucosaminidases from Jack beans. Compounds 3b and 15 are much weaker inhibitors of a-L-fucosidases from bovine kidney (44% for 3b and 17% for 15, at 1 mM concentration) and did not inhibit the other enzymes. Compound 15, epimer of 3a at C-6, showed a weak inhibition towards a-L-fucosidases indicating the importance of the S configuration at Me-6 to bind the enzyme.
In summary, the synthesis of new C-3-substituted fucoconfigurated hydroxylated hexahydropyridazines from Dlyxose is reported. They can be considered as the first examples of aza-C-glycosides having a biimino (-NH-NH-) moiety and constitute interesting lead compounds for the search of new a-L-fucosidase inhibitors. In spite of that compound 3b is a weak inhibitor of a-L-fucosidases, its triamino functionality makes it a promising candidate for the discovery of fucosidase inhibitors by combinatorial procedures through the approach of dynamic libraries of imines 20 or through the in situ evaluation of libraries of amides. 7 The use of lead compounds 3a and 3b in the synthesis of new derivatives, the conformational analysis and the corresponding biological studies are currently in progress in our laboratory and will be reported in due course.
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